Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LepVax (Access to Advanced Health Institute)
- Development stage
- Phase 1
- Lead developer
- American Leprosy Missions
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
LepVax is a recombinant protein subunit vaccine candidate developed by the Access to Advanced Health Institute (AAHI) for the prevention and potentially the treatment of leprosy. The vaccine is a combination of the LEP-F1 fusion protein and the GLA-SE adjuvant. LEP-F1 is a chimeric protein comprising four highly immunogenic antigens from Mycobacterium leprae: ML2531, ML2380, ML2028, and ML1642. GLA-SE (Glucopyranosyl Lipid Adjuvant in a Stable Emulsion) is a synthetic Toll-like receptor 4 (TLR4) agonist that enhances the magnitude and quality of the Th1-type immune response, which is critical for controlling M. leprae infection. LepVax aims to provide long-lasting protective immunity and reduce the incidence of leprosy-related nerve damage. It has been evaluated in Phase 1 clinical trials for safety and immunogenicity in healthy volunteers.
- Brand names
- LepVax
- Other names
- LEP-F1 + GLA-SE
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on LepVax (Access to Advanced Health Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LepVax (Access to Advanced Health Institute).